Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Single and Multiple Ascending Dose Study of KK3910 in Healthy Volunteers and Patients with Essential Hypertension
jRCT2031240676Phase 1Recruiting
- Sponsor
- Kyowa Kirin
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KK3910 in essential hypertension (6 arms), sponsored by Kyowa Kirin. Primary endpoint: Number of participants with adverse events. Started Apr 2025; status: recruiting.
02
Drugs
KK3910
03
Conditions
essential hypertension
Beyond the preview
Go deeper on jRCT2031240676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240676.